Signal your own growth hormone. Do not replace it.
Compounded sermorelin is an upstream growth-hormone signal, not synthetic HGH and not a bodybuilding product.
About 10 minutes. No charge unless your clinician approves.
Start upstream.
Growth hormone gets the attention. The signal that tells your pituitary to release it is the more interesting place to start.
Sermorelin is a synthetic analog of growth hormone releasing hormone, or GHRH. Rather than supplying growth hormone directly, it stimulates the pituitary to release the growth hormone your own endocrine system produces. The treatment acts upstream in the signaling chain instead of replacing the downstream hormone.
Growth hormone secretion is naturally pulsatile, and sermorelin works through the physiology that generates those pulses. That does not turn mechanism into a promise about sleep, muscle, recovery, energy, or body composition. It does give the clinician a specific hormonal axis to evaluate when your goals and history make that conversation appropriate.
Sermorelin signals the body's own growth-hormone system rather than supplying synthetic HGH. Its upstream mechanism and slow-build timeline keep the treatment focused on clinician-guided endocrine care.
Read the evidence →For people asking the upstream question.
The Recovery Question
Training still matters, but recovery feels different from the baseline you remember. You want a clinician to evaluate the hormonal context rather than assume the answer is simply more effort.
The GH-Axis Reader
You understand the difference between administering growth hormone and stimulating its release. You want that physiology discussed seriously, without turning the mechanism into a guaranteed outcome.
The Long-Game Patient
You are interested in endocrine health as a system, not a quick performance effect. A provider-guided plan is the only version of that conversation that interests you.
Compounded sermorelin is not an FDA-approved drug product. Sermorelin is not growth hormone; it signals your pituitary to release its own. A licensed provider determines candidacy from your full intake, and results vary.
This might not be the right fit if:
- You have an active cancer or are in remission. Any active or recent cancer needs oncology clearance before a GH-stimulating plan.
- You are pregnant or breastfeeding.
- You have untreated hypothyroidism. Your thyroid needs to be optimized before starting a GH-axis treatment.
- You have significant pituitary dysfunction or a history of pituitary surgery. That calls for a provider’s evaluation before any GHRH-based treatment.
- You take a medication or carry a condition that deserves a closer look before adding an injectable peptide.
Your intake screens for all contraindications. Every candidate is evaluated by a licensed clinician before any prescription is issued. No prescription is issued without clearance.
Sermorelin, prescribed with care.
Compounded by a licensed 503A pharmacy. Prescribed by a licensed provider after clinical review.
- Clinician review of medical history, medications, endocrine context, and goals
- Sermorelin considered as an upstream GHRH signal rather than administered growth hormone
- Individual prescription prepared by a licensed 503A pharmacy if approved
- Follow-up tied to response, tolerability, and the broader endocrine plan
Prescription issued subject to provider judgment. Results vary. Not a guarantee of outcomes.
*Price reflects a 3 month commitment. Other billing options are shown at checkout.
More in Performance & Recovery.
NAD+
Cellular energy has a supply chain.
Compounded injectable NAD+ with supplies, pharmacy fulfillment, and clinician guidance built around the route.
Glutathione
Antioxidant defense, under clinical direction.
Compounded injectable glutathione for clinician-guided antioxidant defense beyond the supplement aisle.
Tesamorelin
Visceral fat is the specific target studied.
Compounded tesamorelin centered on the molecule's studied visceral-fat pathway and the medical oversight it deserves.
What the research shows
In children with growth hormone deficiency, height velocity rose from 4.1 to 8.0 cm a year.
The detail
In a multicenter open-label study, 110 previously untreated prepubertal children with growth hormone deficiency received sermorelin, GHRH(1-29), at 30 micrograms per kilogram subcutaneously once nightly, and mean height velocity rose from 4.1 centimeters per year at baseline to 8.0 at 6 months and 7.2 at 12 months.1
GHRH raised growth hormone and IGF-1 to levels seen in healthy young men.
The detail
In a randomized crossover study in 10 healthy men of mean age 68, GHRH(1-29) self-injected subcutaneously twice daily for 14 days raised mean 24-hour growth hormone and IGF-1 at the 1 milligram dose to levels no longer different from those measured in healthy young men, with no change in fasting glucose, blood pressure, or chemistry and hematology profiles.2
Nightly GHRH raised nocturnal growth hormone but did not change IGF-1, weight or DEXA measures.
The detail
In an open six-week study in 11 healthy non-obese men aged 64 to 76 with low baseline IGF-1, nightly self-injected GHRH(1-29) at 2 milligrams increased mean nocturnal growth hormone release and growth hormone peak amplitude but did not change IGF-1, IGF binding protein 3, body weight, or DEXA measures of muscle and fat; 2 of 6 measures of muscle strength improved.3
Lean body mass rose in the men only, and the IGF-1 rise faded by week 16.
The detail
In a single-blind, randomized, placebo-controlled study in 19 men and women aged 55 to 71, 16 weeks of nightly [Nle27]GHRH(1-29)NH2 at 10 micrograms per kilogram increased nocturnal growth hormone, IGF-1 and skin thickness, and increased lean body mass in the men only, while body weight and self-reported sleep quality were unchanged and the IGF-1 rise returned toward baseline by week 16.4
What it does not show
No randomized trial has tested compounded sermorelin for sleep, recovery, energy or aging.
The detail
There are no randomized controlled trials establishing that compounded sermorelin improves sleep, recovery, energy, body composition or any aging outcome in adults who do not have diagnosed growth hormone deficiency.
The height-velocity result came from children with diagnosed deficiency and had no control group.
The detail
The height-velocity result comes from prepubertal children with diagnosed growth hormone deficiency in an open-label study without a control group. That is a different population, indication and endpoint from adult use.
Growth hormone and IGF-1 are intermediates; weight, fat mass and sleep did not change.
The detail
Growth hormone and IGF-1 are measured intermediates, not clinical outcomes. In the adult studies above the hormone response was not accompanied by a change in body weight or in fat mass, sleep quality was unaffected, and in one study nightly dosing raised growth hormone without raising IGF-1 at all.
The compounded preparation is not the discontinued approved product, and the adult studies were small.
The detail
Geref, the sermorelin product that once held an approved United States label, has been discontinued; the compounded preparation offered here is not that product and has not been studied as a finished drug product. The adult GHRH studies cited here ran from 2 weeks to 5 months in groups of 10 to 19 people, which is too small and too short to describe long-term safety or benefit.
- Thorner M, et al. Once daily subcutaneous growth hormone-releasing hormone therapy… J Clin Endocrinol Metab. 1996.
- Corpas E, et al. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the… J Clin Endocrinol Metab. 1992.
- Vittone J, et al. Effects of single nightly injections of growth hormone-releasing… Metabolism. 1997.
- Khorram O, et al. Endocrine and metabolic effects of long-term administration of… J Clin Endocrinol Metab. 1997.
Serious risks
- A large proportion of treated patients developed antibodies to the peptide, an effect whose clinical significance was never established
- Sermorelin is prohibited at all times by the World Anti-Doping Agency, so if you are a tested athlete, say so at intake
Commonly reported
- Mostly local: pain, swelling or redness where you inject, the most common finding on the brand label before that product was discontinued
- Reported less often: flushing, headache, nausea, dizziness, drowsiness, difficulty swallowing and hives
Because sermorelin works by pushing your own pituitary to release growth hormone, your provider screens for active or recent cancer, for pituitary disease or prior pituitary surgery, and for untreated hypothyroidism, which is addressed before a growth hormone axis treatment starts. The compounded preparation offered here is not the discontinued labeled product, and safety data for using it this way is limited, which is the reason this sits with a clinician rather than in a shopping cart.
Asked and answered.
You are not charged, and you are not left guessing. Your clinician explains the reasoning and, where it helps, what a better path might look like. Reviews are typically completed in under 24 hours.
Exogenous growth hormone supplies growth hormone directly. Sermorelin is a GHRH analog that stimulates the pituitary to release endogenous growth hormone. They act at different points in the same hormonal axis, and that distinction is central to how a clinician evaluates them.
Your provider sets expectations for your case and reviews what actually happens. The mechanism alone does not justify a universal promise about sleep, recovery, energy, body composition, or a particular timeline.
The compounded sermorelin preparation offered here is not an FDA-approved finished drug product. No compounded medication is FDA-approved, including this one. Compounded medicines are made to your individual prescription by a licensed pharmacy rather than manufactured and approved as a finished drug product.
Any time, before your renewal date. No phone calls required.